Статті в журналах: "Peptides drug delivery"

1

Berillo, Dmitriy, Adilkhan Yeskendir, Zharylkasyn Zharkinbekov, Kamila Raziyeva, and Arman Saparov. "Peptide-Based Drug Delivery Systems." Medicina 57, no. 11 (November 5, 2021): 1209. http://dx.doi.org/10.3390/medicina57111209.

Повний текст джерела

Анотація:

Peptide-based drug delivery systems have many advantages when compared to synthetic systems in that they have better biocompatibility, biochemical and biophysical properties, lack of toxicity, controlled molecular weight via solid phase synthesis and purification. Lysosomes, solid lipid nanoparticles, dendrimers, polymeric micelles can be applied by intravenous administration, however they are of artificial nature and thus may induce side effects and possess lack of ability to penetrate the blood-brain barrier. An analysis of nontoxic drug delivery systems and an establishment of prospective trends in the development of drug delivery systems was needed. This review paper summarizes data, mainly from the past 5 years, devoted to the use of peptide-based carriers for delivery of various toxic drugs, mostly anticancer or drugs with limiting bioavailability. Peptide-based drug delivery platforms are utilized as peptide–drug conjugates, injectable biodegradable particles and depots for delivering small molecule pharmaceutical substances (500 Da) and therapeutic proteins. Controlled drug delivery systems that can effectively deliver anticancer and peptide-based drugs leading to accelerated recovery without significant side effects are discussed. Moreover, cell penetrating peptides and their molecular mechanisms as targeting peptides, as well as stimuli responsive (enzyme-responsive and pH-responsive) peptides and peptide-based self-assembly scaffolds are also reviewed.

Стилі APA, Harvard, Vancouver, ISO та ін.

2

T. Varkey, Jaya. "Peptides-Incorporated Nanoparticles for Imaging and Drug Delivery Applications." Journal of Pharmaceutical and Medicinal Chemistry 2, no. 2 (2016): 145–48. http://dx.doi.org/10.21088/jpmc.2395.6615.2216.4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Preet, Payal. "PEPTIDES: A NEW THERAPEUTIC APPROACH." International Journal of Current Pharmaceutical Research 10, no. 2 (March 15, 2018): 29. http://dx.doi.org/10.22159/ijcpr.2018v10i2.25887.

Повний текст джерела

Анотація:

Peptide therapeutics have played a notable role in medical practice since the advent of insulin therapy in the 1920s. Over 60 peptide drugs are approved in the United States and other major markets, and peptides continue to enter clinical development at a steady pace. Peptide drug discovery has diversified beyond its traditional focus on endogenous human peptides to include a broader range of structures identified from other natural sources or through medicinal chemistry efforts. Peptides are recognized for being highly selective and efficacious and, at the same time, relatively safe and well tolerated. Consequently, there is an increased interest in peptides in pharmaceutical research and development (R and D), and approximately 140 peptide therapeutics are currently being evaluated in clinical trials. Given that the low-hanging fruits in the form of obvious peptide targets have already been picked, it has now become necessary to explore new routes beyond traditional peptide design. Examples of such approaches are multifunctional and cell-penetrating peptides, as well as peptide drug conjugates. In regards to patient compliance for drug delivery, oral drug delivery is generally the preferred route of administration. However, parental injection of peptide drugs has always been the primary method of peptide drug administration. Nevertheless, oral delivery of peptide drug presents a significant challenge due to the enzymatic degradation by enzymes in the GI tract and the poor penetration of the peptides across gastro-intestinal epithelium membranes, particularly for adults. Therefore, a novel peptide drug analogue or pro-drug that both protect peptide drugs from degradation by the enzymes in the GI tract that also improves its penetration across the intestinal epithelium membrane would greatly advance the development of peptide drugs as effective candidates for the treatment of various diseases.

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Peng, Fei, Wensheng Zhang, and Feng Qiu. "Self-assembling Peptides in Current Nanomedicine: Versatile Nanomaterials for Drug Delivery." Current Medicinal Chemistry 27, no. 29 (September 2, 2020): 4855–81. http://dx.doi.org/10.2174/0929867326666190712154021.

Повний текст джерела

Анотація:

Background: The development of modern nanomedicine greatly depends on the involvement of novel materials as drug delivery system. In order to maximize the therapeutic effects of drugs and minimize their side effects, a number of natural or synthetic materials have been widely investigated for drug delivery. Among these materials, biomimetic self-assembling peptides (SAPs) have received more attention in recent years. Considering the rapidly growing number of SAPs designed for drug delivery, a summary of how SAPs-based drug delivery systems were designed, would be beneficial. Method: We outlined research works on different SAPs that have been investigated as carriers for different drugs, focusing on the design of SAPs nanomaterials and how they were used for drug delivery in different strategies. Results: Based on the principle rules of chemical complementarity and structural compatibility, SAPs such as ionic self-complementary peptide, peptide amphiphile and surfactant-like peptide could be designed. Determined by the features of peptide materials and the drugs to be delivered, different strategies such as hydrogel embedding, hydrophobic interaction, electrostatic interaction, covalent conjugation or the combination of them could be employed to fabricate SAPs-drug complex, which could achieve slow release, targeted or environment-responsive delivery of drugs. Furthermore, some SAPs could also be combined with other types of materials for drug delivery, or even act as drug by themselves. Conclusion: Various types of SAPs have been designed and used for drug delivery following various strategies, suggesting that SAPs as a category of versatile nanomaterials have promising potential in the field of nanomedicine.

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Dahiya, Sunita, and Rajiv Dahiya. "BIOAVAILABILITY ENHANCEMENT AND LIPID NANOCARRIER BASED DELIVERY OF PEPTIDES AND PROTEINS." Bulletin of Pharmaceutical Research 10, no. 1-3 (2020): 1–10. http://dx.doi.org/10.21276/bpr.2020.10.3.

Повний текст джерела

Анотація:

Peptides and proteins are vital biomacromolecules that perform several bodily functions in various physiological and biological processes. Being biocompatible and biodegradable, these macromolecules are considered promising platforms for delivery of drugs and genes. However, peptides and proteins suffer from major limitations including enzymatic degradation, short circulation half-lives, and poor membrane permeability that leads to poor bioavailability, challenging their effective delivery. This article briefly discusses the inherent challenges in peptide and protein delivery along with strategies for bioavailability enhancement and lipid nanocarriers as prospective systems for peptide and protein drug delivery.

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Tesauro, Diego, Antonella Accardo, Carlo Diaferia, Vittoria Milano, Jean Guillon, Luisa Ronga, and Filomena Rossi. "Peptide-Based Drug-Delivery Systems in Biotechnological Applications: Recent Advances and Perspectives." Molecules 24, no. 2 (January 19, 2019): 351. http://dx.doi.org/10.3390/molecules24020351.

Повний текст джерела

Анотація:

Peptides of natural and synthetic sources are compounds operating in a wide range of biological interactions. They play a key role in biotechnological applications as both therapeutic and diagnostic tools. They are easily synthesized thanks to solid-phase peptide devices where the amino acid sequence can be exactly selected at molecular levels, by tuning the basic units. Recently, peptides achieved resounding success in drug delivery and in nanomedicine smart applications. These applications are the most significant challenge of recent decades: they can selectively deliver drugs to only pathological tissues whilst saving the other districts of the body. This specific feature allows a reduction in the drug side effects and increases the drug efficacy. In this context, peptide-based aggregates present many advantages, including biocompatibility, high drug loading capacities, chemical diversity, specific targeting, and stimuli responsive drug delivery. A dual behavior is observed: on the one hand they can fulfill a structural and bioactive role. In this review, we focus on the design and the characterization of drug delivery systems using peptide-based carriers; moreover, we will also highlight the peptide ability to self-assemble and to actively address nanosystems toward specific targets.

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Wang, Qian, Nan Jiang, Bo Fu, Fan Huang, and Jianfeng Liu. "Self-assembling peptide-based nanodrug delivery systems." Biomaterials Science 7, no. 12 (2019): 4888–911. http://dx.doi.org/10.1039/c9bm01212e.

Повний текст джерела

Анотація:

The present review outlines the methods designing self-assembling peptide-based NDDs for small molecule drugs, with an emphasis on the different drug delivery strategies and their applications in using peptides and peptide conjugates.

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Huang, Wenzhe. "Peptide-based Drug Delivery for Curing Cancer." Journal of Drug Delivery and Therapeutics 9, no. 1-s (February 15, 2019): 387–89. http://dx.doi.org/10.22270/jddt.v9i1-s.2338.

Повний текст джерела

Анотація:

Peptides have numerous advantages as the chains help treat cancer, tumor and several complex diseases. The review details on the different structures of peptides that can ensure actual and efficient delivery of therapy to tumor and cancer cases. The co-delivery system mainly aims to improve the therapeutic delivery process regarding manufacturing, targeting, and impact. Keywords: Nanotechnology, Peptide-based Drug Delivery, cancer

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Lakshmi, P. k., D. Prasanthi, and B. Veeresh. "NON INVASIVE DELIVERY OF PROTEIN AND PEPTIDE DRUGS: A REVIEW." Asian Journal of Pharmaceutical and Clinical Research 10, no. 8 (August 1, 2017): 25. http://dx.doi.org/10.22159/ajpcr.2017.v10i8.18274.

Повний текст джерела

Анотація:

Till recent, injections remained the most common route for administration of protein and peptide drugs because of their poor bioavailability in the other routes. Because it is generally recognized that injection based delivery is a major impediment to the commercial success of therapeutic proteins and peptides, research in both academia and industry continues to focus on ways to overcome this problem. Possible non-parenteral administration routes for delivery of peptide and protein drugs include oral, nasal, ocular, transdermal, rectal, colonic, and vaginal route. The large surface area associated with most of these routes makes them attractive targets for drug delivery. While non-invasive administration by these routes is considered a more logical and achievable option for local treatment regimens, systemic delivery of proteins and peptides is significantly more challenging. In spite of effort made on the development of drugs for these routes, most of the successes fail to address how the technology will be transformed to a commercial product. The only notable exceptions have been the successful commercialization of nasal formulations for systemic delivery of a limited number of therapeutic peptides, and recent regulatory approvals of both pulmonary and buccal delivery systems for systemic delivery of insulin and an oral formulation of a small peptide analog, cyclosporine, have been commercialized. The present review aims to discuss the potential non-invasive routes of protein and peptide drug delivery. The factors which will affect drug transport and the bioavailability of proteins administered through these routes is also emphasized

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Cerrato, Carmine Pasquale, Tõnis Lehto, and Ülo Langel. "Peptide-based vectors: recent developments." Biomolecular Concepts 5, no. 6 (December 1, 2014): 479–88. http://dx.doi.org/10.1515/bmc-2014-0024.

Повний текст джерела

Анотація:

AbstractPeptides and peptide-cargo complexes have been used for drug delivery and gene therapy. One of the most used delivery vectors are cell-penetrating peptides, due to their ability to be taken up by a variety of cell types and deliver a large variety of cargoes through the cell membrane with low cytotoxicity. In vitro and in vivo studies have shown their possibility and full effectiveness to deliver oligonucleotides, plasmid DNA, small interfering RNAs, antibodies, and drugs. We report in this review some of the latest strategies for peptide-mediated delivery of nucleic acids. It focuses on peptide-based vectors for therapeutic molecules and on nucleic acid delivery. In addition, we discuss recent applications and clinical trials.

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Kim, WonJu, and Je-Min Choi. "Development of a novel transcutaneous delivery peptide and its application in skin inflammation (HYP7P.273)." Journal of Immunology 194, no. 1_Supplement (May 1, 2015): 191.21. http://dx.doi.org/10.4049/jimmunol.194.supp.191.21.

Повний текст джерела

Анотація:

Abstract Transcutaneous delivery of therapeutic drugs has many advantages over the systemic administration for inflammatory skin diseases such as atopic dermatitis or psoriasis. However, the greatest challenge for transcutaneous delivery is methodology due to the tight junction of skin tissue. Here, we screened and identified transdermal delivery peptide (TDP) from human proteins which would be non-invasive and simple method to deliver various cargos such as chemicals, peptides, proteins, etc. TDP-EGFP recombinant protein was purified and exhibited significantly higher intracellular transduction efficacy compared with TAT-EGFP in Jurkat, HaCaT, NIH3T3 cell lines and also in primary cells including splenocytes and keratinocytes. TDP-TAMRA peptides were successfully delivered into the epidermis and dermis of the mouse ear and back skin. We also used TDP-VIVIT peptide to inhibit T cell activation and contact dermatitis in vivo. TDP-VIVIT significantly inhibited IL-2 secretion with reduction of CD69 and CD44 expression level of activated CD4 and CD8 T cells. Our results suggest TDP-VIVIT peptide could be a potential transdermal applicable therapeutic drug for inflammatory skin diseases.

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Salave, Sagar, Dhwani Rana, and Derajram Benival. "Peptide Functionalised Nanocarriers for Bone Specific Delivery of PTH (1-34) in Osteoporosis." Current Nanomedicine 11, no. 3 (September 2021): 142–48. http://dx.doi.org/10.2174/2468187312666211220112324.

Повний текст джерела

Анотація:

: Osteoporosis represents a major public health burden especially considering the aging population worldwide. Treatment modalities for osteoporosis are classified into two categories based on the effect on bone remodelling: anabolic drugs and antiresorptive drugs. Anabolic drugs are preferred as it stimulates new bone formation. Currently, PTH (1-34) is the only peptide-based drug approved as an anabolic agent for the treatment of osteoporosis by both USFDA as well as EMA. However, its non-specific delivery results in prolonged kidney exposure, causing hypercalcemia. Nanotechnology-based drug delivery systems functionalized by conjugating it with homing moieties, such as peptides, offer an advantage of targeted delivery with reduced off-target effects. Here, we propose an innovative and targeted nanovesicle approach to efficiently deliver PTH (1-34) to the bone surface using peptides as a homing moiety. The proposed innovative delivery approach will augment the specific interaction between the drug and bone surface without producing side effects. This will reduce the off-target effects of PTH (1-34), and at the same time, it will also improve the outcome of anabolic therapy. Therefore, we postulate that the proposed innovative drug delivery approach for PTH (1-34) will establish as a promising therapy for osteoporotic patients, specifically in postmenopausal women who are at greater risk of bone fracture.

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Shah, Vatsal R., Yamini D. Shah, and Mansi N. Athalye. "Novel approaches in development of cell penetrating peptides." Journal of Applied Pharmaceutical Research 9, no. 1 (March 15, 2021): 1–7. http://dx.doi.org/10.18231/joapr.2021.9.1.08.24.

Повний текст джерела

Анотація:

Therapeutic cargos which are impermeable to the cell can be delivered by cell penetrating peptides (CPPs). CPP-cargo complexes accumulate by endocytosis inside the cells but they fail to reach the cytosolic space properly as they are often trapped in the endocytic organelles. Here the CPP mediated endosomal escape and some strategies used to increase endosomal escape of CPP-cargo conjugates are discussed with evidence. Potential benefits can be obtained by peptides such as reduction in side effects, biocompatibility, easier synthesis and can be obtained at lower administered doses. The particular peptide known as cell penetrating peptides are able to translocate themselves across membrane with the carrier drugs with different mechanisms. This is of prime importance in drug delivery systems as they have capability to cross physiological membranes. This review describes various mechanisms for effective drug delivery and associated challenges

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Fernández-Carneado, Jimena, Marcelo J. Kogan, Silvia Pujals, and Ernest Giralt. "Amphipathic peptides and drug delivery." Biopolymers 76, no. 2 (2004): 196–203. http://dx.doi.org/10.1002/bip.10585.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Li, Shuzhen, Wanqiong Li, Xin Yang, Yanfeng Gao, and Guanyu Chen. "Dietary-Polysaccharide-Modified Fish-Oil-Based Double Emulsion as a Functional Colloidal Formulation for Oral Drug Delivery." Pharmaceutics 14, no. 12 (December 19, 2022): 2844. http://dx.doi.org/10.3390/pharmaceutics14122844.

Повний текст джерела

Анотація:

Oral delivery is the most convenient drug administration route. However, oral delivery of peptides is extremely challenging due to the physical and chemical barriers within the gastrointestinal tract. Polysaccharides are often utilized as polymeric biomaterials in drug delivery. Among these, dietary polysaccharides extracted from okra, yam, and spirulina have been reported to stimulate innate immunity with well-known nutritional benefits. In this study, we developed a dietary-polysaccharide-modified fish-oil-based emulsion for oral co-delivery of a hydrophilic PD-L1 blocking peptide and the hydrophobic small molecule simvastatin. The optimal emulsion was nano-sized and exhibited a negative surface charge, high drug encapsulation efficiency of over 97%, low viscosity, and sustained drug release manner. The formulation could significantly increase the uptake of peptides by intestinal Caco-2 cells, which demonstrated the great potential of the formulation for promoting the oral absorption of peptides. Additionally, these dietary polysaccharides could promote dendritic cell maturation and cytokine expression in macrophages, demonstrating that these nutraceutical polysaccharides had dual roles of functioning as promising colloidal delivery systems and as potential immune modulators or adjuvants. Thus, this food-based colloidal delivery system shows promise for the oral delivery of peptide drugs and lays a great platform for future applications in immunotherapy.

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Jayaraman, Arthi, Christopher Price, Millicent O. Sullivan, and Kristi L. Kiick. "Collagen-Peptide-Based Drug Delivery Strategies." Technology & Innovation 21, no. 4 (December 1, 2020): 1–20. http://dx.doi.org/10.21300/21.4.2020.9.

Повний текст джерела

Анотація:

Collagen-targeting strategies have proven to be an effective method for targeting drugs to pathological tissues for treatment of disease. The use of collagen-like peptides for controlling the assembly of drug delivery vehicles, as well as their integration into collagen-containing matrices, offers significant advantages for tuning the morphologies of assembled structures, their thermoresponsiveness, and the loading and release of both small-molecule and macro-molecular cargo. In this contribution, we summarize the design and development of collagen-peptide-based drug delivery systems introduced by the Kiick group and detail the expansion of our understanding and the application of these unique molecules through collaborations with experts in computational simulations (Jayaraman), osteoarthritis (Price), and gene delivery (Sullivan). Kiick was inducted as a Fellow of the National Academy of Inventors in 2019 and was to deliver an address describing the innovations of her research. Given the cancellation of the NAI Annual Meeting as a result of coronavirus travel restrictions, her work based on collagen-peptide-mediated assembly is instead summarized in this contribution.

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Penate Medina, Oula, Merja Haikola, Marja Tahtinen, Ilkka Simpura, Sami Kaukinen, Heli Valtanen, Ying Zhu, et al. "Liposomal Tumor Targeting in Drug Delivery Utilizing MMP-2- and MMP-9-Binding Ligands." Journal of Drug Delivery 2011 (December 29, 2011): 1–9. http://dx.doi.org/10.1155/2011/160515.

Повний текст джерела

Анотація:

Nanotechnology offers an alternative to conventional treatment options by enabling different drug delivery and controlled-release delivery strategies. Liposomes being especially biodegradable and in most cases essentially nontoxic offer a versatile platform for several different delivery approaches that can potentially enhance the delivery and targeting of therapies to tumors. Liposomes penetrate tumors spontaneously as a result of fenestrated blood vessels within tumors, leading to known enhanced permeability and subsequent drug retention effects. In addition, liposomes can be used to carry radioactive moieties, such as radiotracers, which can be bound at multiple locations within liposomes, making them attractive carriers for molecular imaging applications. Phage display is a technique that can deliver various high-affinity and selectivity peptides to different targets. In this study, gelatinase-binding peptides, found by phage display, were attached to liposomes by covalent peptide-PEG-PE anchor creating a targeted drug delivery vehicle. Gelatinases as extracellular targets for tumor targeting offer a viable alternative for tumor targeting. Our findings show that targeted drug delivery is more efficient than non-targeted drug delivery.

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Kumar, Vinod, Sumeet Patiyal, Anjali Dhall, Neelam Sharma, and Gajendra Pal Singh Raghava. "B3Pred: A Random-Forest-Based Method for Predicting and Designing Blood–Brain Barrier Penetrating Peptides." Pharmaceutics 13, no. 8 (August 11, 2021): 1237. http://dx.doi.org/10.3390/pharmaceutics13081237.

Повний текст джерела

Анотація:

The blood–brain barrier is a major obstacle in treating brain-related disorders, as it does not allow the delivery of drugs into the brain. We developed a method for predicting blood–brain barrier penetrating peptides to facilitate drug delivery into the brain. These blood–brain barrier penetrating peptides (B3PPs) can act as therapeutics, as well as drug delivery agents. We trained, tested, and evaluated our models on blood–brain barrier peptides obtained from the B3Pdb database. First, we computed a wide range of peptide features. Then, we selected relevant peptide features. Finally, we developed numerous machine-learning-based models for predicting blood–brain barrier peptides using the selected features. The random-forest-based model performed the best with respect to the top 80 selected features and achieved a maximal 85.08% accuracy with an AUROC of 0.93. We also developed a webserver, B3pred, that implements our best models. It has three major modules that allow users to predict/design B3PPs and scan B3PPs in a protein sequence.

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Liu, Yarong, Man Ji, Michael K. Wong, Kye-Il Joo, and Pin Wang. "Enhanced Therapeutic Efficacy of iRGD-Conjugated Crosslinked Multilayer Liposomes for Drug Delivery." BioMed Research International 2013 (2013): 1–11. http://dx.doi.org/10.1155/2013/378380.

Повний текст джерела

Анотація:

Targeting nanoparticles by conjugating various specific ligands has shown potential therapeutic efficacy in nanomedicine. However, poor penetration of antitumor drugs into solid tumors remains a major obstacle. Here, we describe a targeting strategy for antitumor drug delivery by conjugating a crosslinked multilamellar liposomal vesicle (cMLV) formulation with a tumor-penetrating peptide, iRGD. The results showed that iRGD peptides could facilitate the binding and cellular uptake of drug-loaded cMLVs and consequently enhance the antitumor efficacy in breast tumor cells, including multidrug-resistant cells. Moreover, colocalization data revealed that iRGD-conjugated cMLVs (iRGD-cMLVs) entered cells via the clathrin-mediated pathway, followed by endosome-lysosome transport for efficient drug delivery. Finally,in vivostudy indicated that iRGD-cMLVs could deliver anticancer drugs efficiently to mediate significant tumor suppression.

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Wang, B., W. Wang, J. Jiang, and C. E. Ballard. "Prodrug Approaches to the Improved Delivery of Peptide Drugs." Current Pharmaceutical Design 5, no. 4 (April 1999): 265–87. http://dx.doi.org/10.2174/1381612805666230109214307.

Повний текст джерела

Анотація:

Undesirable pharmaceutical and biopharmaceutical properties, which include low water solubility, poor stability, and low permeability through biological membrane barriers, often hinder the clinical development of biologically active peptides. Finding solutions to these problems is a contemporary issue in developing clinically the vast number of biologically active peptides as drugs. In recent years, significant progress has been made in developing prodrug approaches for the improvement of the water solubility, stability, and membrane permeability of peptides. For improving water solubility, the focus has been on the bioreversible introduction of ionizable functional groups to peptides, which helps to increase the polarity and thus water solubility of the peptide drugs. For improving stability, efforts have focused on stabilizing peptides against exopeptit.lase-mediated hydrolysis by bioreversibly masking the terminal carboxyl and/or amino groups. For improving permeability through biological barriers, recent efforts have focused on both improving the lipophilicity of a peptide in order to facilitate its passive permeation through biological membranes and conjugation of a peptide to a carrier which allows for the active transport of the peptide-carrier conjugate. Many of the prodrug systems developed recently have the potential to be used clinically for the delivery of peptide drugs to the desired site of action.

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Furman, Olga, Alisa Zaporozhets, Dror Tobi, Andrii Bazylevich, Michael A. Firer, Leonid Patsenker, Gary Gellerman, and Bat Chen R. Lubin. "Novel Cyclic Peptides for Targeting EGFR and EGRvIII Mutation for Drug Delivery." Pharmaceutics 14, no. 7 (July 20, 2022): 1505. http://dx.doi.org/10.3390/pharmaceutics14071505.

Повний текст джерела

Анотація:

The epidermal growth factor–epidermal growth factor receptor (EGF-EGFR) pathway has become the main focus of selective chemotherapeutic intervention. As a result, two classes of EGFR inhibitors have been clinically approved, namely monoclonal antibodies and small molecule kinase inhibitors. Despite an initial good response rate to these drugs, most patients develop drug resistance. Therefore, new treatment approaches are needed. In this work, we aimed to find a new EGFR-specific, short cyclic peptide, which could be used for targeted drug delivery. Phage display peptide technology and biopanning were applied to three EGFR expressing cells, including cells expressing the EGFRvIII mutation. DNA from the internalized phage was extracted and the peptide inserts were sequenced using next-generation sequencing (NGS). Eleven peptides were selected for further investigation using binding, internalization, and competition assays, and the results were confirmed by confocal microscopy and peptide docking. Among these eleven peptides, seven showed specific and selective binding and internalization into EGFR positive (EGFR+ve) cells, with two of them—P6 and P9—also demonstrating high specificity for non-small cell lung cancer (NSCLC) and glioblastoma cells, respectively. These peptides were chemically conjugated to camptothecin (CPT). The conjugates were more cytotoxic to EGFR+ve cells than free CPT. Our results describe a novel cyclic peptide, which can be used for targeted drug delivery to cells overexpressing the EGFR and EGFRvIII mutation.

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Song, Yingzhuo, Tao Zhang, Huiguang Cheng, Wei Jiang, Pu Li, Jun Zhang, and Zhanhai Yin. "Imidazolium-Based Ionic Liquid-Assisted Preparation of Nano-Spheres Loaded with Bio-Active Peptides to Decrease Inflammation in an Osteoarthritis Model: Ex Vivo Evaluations." Journal of Biomedical Nanotechnology 17, no. 5 (May 1, 2021): 859–72. http://dx.doi.org/10.1166/jbn.2021.3069.

Повний текст джерела

Анотація:

Osteoarthritis is one of the most prevalent chronic diseases. Cartilage inflammation in osteoarthritis results from pain in articular joints. Anti-inflammatory drugs provide relief by hindering the production of pro-inflammatory cytokines and interleukin-6. Targeted delivery of anti-inflammatory drugs is very effective in the treatment of osteoarthritis. This approach reduces the usage of therapeutic drug dosages and unwanted side effects. Here, we fabricated a non-invasive and efficient targeted drug delivery system to reduce persistent inflammation in an osteoarthritis model. Temperature-sensitive hollow dextran/poly(N-isopropyl acrylamide) nanoparticles were synthesized by the destruction of N,N’-bis(acryloyl)cystamine crosslinked cores in imidazolium-based ionic liquids. The copolymerized 2-acrylamido-2-methylpropane sulfonic acid created sulfur functionalities that increase the loading of therapeutic KAFAK peptides. The chemical structure of the polymer nanoparticles was analyzed with UV-Visible, Fourier transform infrared, and X-ray photoelectron spectroscopy. The thermal responsive characteristics of the nanoparticles were determined with dynamic light scattering, scanning electron microscopy, and transmission electron microscopy analyses. Moreover, the synthesized nanoparticles were used as drug carriers to reduce inflammation in an Ex Vivo osteoarthritis model. The KAFAK-loaded hollow dextran/PNIPAM nanoparticles effectively delivered therapeutic peptides in cartilage explants to suppress inflammation. These thermoresponsive nanoparticles could be an effective drug delivery system to deliver anti-inflammatory therapeutic peptides in a highly osteoarthritic environment.

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Fan, Taotao, Xiaoyan Yu, Bing Shen, and Leming Sun. "Peptide Self-Assembled Nanostructures for Drug Delivery Applications." Journal of Nanomaterials 2017 (2017): 1–16. http://dx.doi.org/10.1155/2017/4562474.

Повний текст джерела

Анотація:

Peptide self-assembled nanostructures are very popular in many biomedical applications. Drug delivery is one of the most promising applications among them. The tremendous advantages for peptide self-assembled nanostructures include good biocompatibility, low cost, tunable bioactivity, high drug loading capacities, chemical diversity, specific targeting, and stimuli responsive drug delivery at disease sites. Peptide self-assembled nanostructures such as nanoparticles, nanotubes, nanofibers, and hydrogels have been investigated by many researchers for drug delivery applications. In this review, the underlying mechanisms for the self-assembled nanostructures based on peptides with different types and structures are introduced and discussed. Peptide self-assembled nanostructures associated promising drug delivery applications such as anticancer drug and gene drug delivery are highlighted. Furthermore, peptide self-assembled nanostructures for targeted and stimuli responsive drug delivery applications are also reviewed and discussed.

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Hu, Zhenhua, Sara Nizzero, Shreya Goel, Louis E. Hinkle, Xiaoyan Wu, Chao Li, Mauro Ferrari, and Haifa Shen. "Molecular targeting of FATP4 transporter for oral delivery of therapeutic peptide." Science Advances 6, no. 14 (April 2020): eaba0145. http://dx.doi.org/10.1126/sciadv.aba0145.

Повний текст джерела

Анотація:

Low oral bioavailability of peptide drugs has limited their application to parenteral administration, which suffers from poor patient compliance. Here, we show that molecular targeting of the FATP4 transporter is an effective approach to specifically transport long-chain fatty acid (LCFA)–conjugated peptides across the enterocytic membrane and, thus, enables oral delivery of drug peptides. We packaged LCFA-conjugated exendin-4 (LCFA-Ex4) into liposomes and coated with chitosan nanoparticles to form an orally deliverable Ex4 (OraEx4). OraEx4 protected LCFA-Ex4 from damage by the gastric fluid and released LCFA-Ex4 in the intestinal cavity, where LCFA-Ex4 was transported across the enterocyte membrane by the FAPT4 transporter. OraEx4 had a high bioavailability of 24.8% with respect to subcutaneous injection and exhibited a substantial hypoglycemic effect in murine models of diabetes mellitus. Thus, molecular targeting of the FATP4 transporter enhances oral absorption of therapeutic peptides and provides a platform for oral peptide drug development.

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Aguiar, Luísa, Arnau Biosca, Elena Lantero, Jiri Gut, Nuno Vale, Philip J. Rosenthal, Fátima Nogueira, David Andreu, Xavier Fernàndez-Busquets, and Paula Gomes. "Coupling the Antimalarial Cell Penetrating Peptide TP10 to Classical Antimalarial Drugs Primaquine and Chloroquine Produces Strongly Hemolytic Conjugates." Molecules 24, no. 24 (December 12, 2019): 4559. http://dx.doi.org/10.3390/molecules24244559.

Повний текст джерела

Анотація:

Recently, we disclosed primaquine cell penetrating peptide conjugates that were more potent than parent primaquine against liver stage Plasmodium parasites and non-toxic to hepatocytes. The same strategy was now applied to the blood-stage antimalarial chloroquine, using a wide set of peptides, including TP10, a cell penetrating peptide with intrinsic antiplasmodial activity. Chloroquine-TP10 conjugates displaying higher antiplasmodial activity than the parent TP10 peptide were identified, at the cost of an increased hemolytic activity, which was further confirmed for their primaquine analogues. Fluorescence microscopy and flow cytometry suggest that these drug-peptide conjugates strongly bind, and likely destroy, erythrocyte membranes. Taken together, the results herein reported put forward that coupling antimalarial aminoquinolines to cell penetrating peptides delivers hemolytic conjugates. Hence, despite their widely reported advantages as carriers for many different types of cargo, from small drugs to biomacromolecules, cell penetrating peptides seem unsuitable for safe intracellular delivery of antimalarial aminoquinolines due to hemolysis issues. This highlights the relevance of paying attention to hemolytic effects of cell penetrating peptide-drug conjugates.

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Lundsten, Sara, Víctor Agmo Hernández, Lars Gedda, Tina Sarén, Christopher J. Brown, David P. Lane, Katarina Edwards, and Marika Nestor. "Tumor-Targeted Delivery of the p53-Activating Peptide VIP116 with PEG-Stabilized Lipodisks." Nanomaterials 10, no. 4 (April 19, 2020): 783. http://dx.doi.org/10.3390/nano10040783.

Повний текст джерела

Анотація:

Stapled peptides targeting the interaction between p53 and its negative regulators MDM2 and MDM4 have exhibited great potential as anti-cancer drugs, albeit with room for improvement in formulation and tumor specificity. Lipid bilayer disks (lipodisks) have emerged as promising drug nanocarriers and can by attachment of targeting moieties be directed selectively towards tumor cells. Tumor-targeted delivery of stapled peptides by use of lipodisks may therefore increase the uptake in the tumors and limit toxicity in healthy tissue. Here, we utilized epidermal growth factor receptor (EGFR)-targeted lipodisks to deliver p53-activating stapled peptide VIP116 to EGFR-expressing tumor cells. We demonstrate that VIP116 can be stably formulated in lipodisks (maximum peptide/lipid molar ratio 0.11). In vitro cell studies verify specific binding of EGF-decorated lipodisks to tumor cells and confirm that targeted delivery of VIP116 significantly decreases tumor cell viability.

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Snyder, Eric L., and Steven F. Dowdy. "Cell Penetrating Peptides in Drug Delivery." Pharmaceutical Research 21, no. 3 (March 2004): 389–93. http://dx.doi.org/10.1023/b:pham.0000019289.61978.f5.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Svensen, Nina, Jeffrey G. A. Walton, and Mark Bradley. "Peptides for cell-selective drug delivery." Trends in Pharmacological Sciences 33, no. 4 (April 2012): 186–92. http://dx.doi.org/10.1016/j.tips.2012.02.002.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Lochmann, Dirk, Edith Jauk, and Andreas Zimmer. "Drug delivery of oligonucleotides by peptides." European Journal of Pharmaceutics and Biopharmaceutics 58, no. 2 (September 2004): 237–51. http://dx.doi.org/10.1016/j.ejpb.2004.03.031.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Yuan, Xin, Yingzhou Qin, Qingmei Tian, Cuijuan Liu, Xiangzhou Meng, Bo Qie, Fan Gao, et al. "Smart delivery of poly-peptide composite for effective cancer therapy." Biomedical Materials 17, no. 2 (January 24, 2022): 024103. http://dx.doi.org/10.1088/1748-605x/ac494c.

Повний текст джерела

Анотація:

Abstract In the past decade, multifunctional peptides have attracted increasing attention in the biomedical field. Peptides possess many impressive advantages, such as high penetration ability, low cost, and etc. However, the short half-life and instability of peptides limit their application. In this study, a poly-peptide drug loading system (called HKMA composite) was designed based on the different functionalities of four peptides. The peptide compositions of HKMA composite from N-terminal to C-terminal were HCBP1, KLA, matrix metalloproteinase-2 (MMP-2)-cleavable peptide and albumin-binding domain. The targeting and lethality of HKMA to NSCLC cell line H460 sphere cells and the half-life of the system were measured in vivo. The results showed that the HKMA composite had a long half-life and specific killing effect on H460 sphere cells in vitro and in vivo. Our result proposed smart peptide drug loading system and provided a potential methodology for effective cancer treatment.

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Golshani, Shiva, Alireza Vatanara, and Mohsen Amin. "Recent Advances in Oral Mucoadhesive Drug Delivery." Journal of Pharmacy & Pharmaceutical Sciences 25 (June 15, 2022): 201–17. http://dx.doi.org/10.18433/jpps32705.

Повний текст джерела

Анотація:

The oral cavity is one of the most important routes for local and systemic drug delivery, as it has a large surface, high permeability, and rich blood supply. Oral mucosal drug delivery has some advantages, such as enhancing bioavailability, preventing first-pass metabolism, reducing dose frequency, and non-invasiveness. In recent years, notable oral mucoadhesive patents were introduced to the pharmaceutical field, which indicates promising potentials for therapeutic purposes. Oral mucosal drug delivery can play a key role to deliver the biological drugs, such as antimicrobial peptides. This article gives an overview of oral mucoadhesive drug delivery systems and provides basic principles for the researchers to overcome the problems associated with the formulation design.

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Er, Simge, Ushna Laraib, Rabia Arshad, Saman Sargazi, Abbas Rahdar, Sadanand Pandey, Vijay Kumar Thakur, and Ana M. Díez-Pascual. "Amino Acids, Peptides, and Proteins: Implications for Nanotechnological Applications in Biosensing and Drug/Gene Delivery." Nanomaterials 11, no. 11 (November 8, 2021): 3002. http://dx.doi.org/10.3390/nano11113002.

Повний текст джерела

Анотація:

Over various scientific fields in biochemistry, amino acids have been highlighted in research works. Protein, peptide- and amino acid-based drug delivery systems have proficiently transformed nanotechnology via immense flexibility in their features for attaching various drug molecules and biodegradable polymers. In this regard, novel nanostructures including carbon nanotubes, electrospun carbon nanofibers, gold nanoislands, and metal-based nanoparticles have been introduced as nanosensors for accurate detection of these organic compounds. These nanostructures can bind the biological receptor to the sensor surface and increase the surface area of the working electrode, significantly enhancing the biosensor performance. Interestingly, protein-based nanocarriers have also emerged as useful drug and gene delivery platforms. This is important since, despite recent advancements, there are still biological barriers and other obstacles limiting gene and drug delivery efficacy. Currently available strategies for gene therapy are not cost-effective, and they do not deliver the genetic cargo effectively to target sites. With rapid advancements in nanotechnology, novel gene delivery systems are introduced as nonviral vectors such as protein, peptide, and amino acid-based nanostructures. These nano-based delivery platforms can be tailored into functional transformation using proteins and peptides ligands based nanocarriers, usually overexpressed in the specified diseases. The purpose of this review is to shed light on traditional and nanotechnology-based methods to detect amino acids, peptides, and proteins. Furthermore, new insights into the potential of amino protein-based nanoassemblies for targeted drug delivery or gene transfer are presented.

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Wang, Qinghua, Shang Cheng, Fen Qin, Ailing Fu, and Chen Fu. "Application progress of RVG peptides to facilitate the delivery of therapeutic agents into the central nervous system." RSC Advances 11, no. 15 (2021): 8505–15. http://dx.doi.org/10.1039/d1ra00550b.

Повний текст джерела

Анотація:

Rabies virus glycoprotein (RVG) peptides have been developed to deliver drugs for CNS diseases. In the present review, RVG-mediated drug delivery systems are summarised, which can deliver almost all small molecules and macromolecule agents.

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Melikov, Kamran, Ann Hara, Kwabena Yamoah, Elena Zaitseva, Eugene Zaitsev, and Leonid V. Chernomordik. "Efficient entry of cell-penetrating peptide nona-arginine into adherent cells involves a transient increase in intracellular calcium." Biochemical Journal 471, no. 2 (October 2, 2015): 221–30. http://dx.doi.org/10.1042/bj20150272.

Повний текст джерела

Анотація:

Mechanisms by which drug-delivery vehicles based on cationic peptides cross cell membranes remain unknown. We report that an increase in intracellular calcium triggered by temperature drop or high peptide concentrations transiently permeabilizes the plasma membrane for nona-arginine (R9) and delivers it to the cytosol.

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Upadhyay, Ravi Kant. "Drug Delivery Systems, CNS Protection, and the Blood Brain Barrier." BioMed Research International 2014 (2014): 1–37. http://dx.doi.org/10.1155/2014/869269.

Повний текст джерела

Анотація:

Present review highlights various drug delivery systems used for delivery of pharmaceutical agents mainly antibiotics, antineoplastic agents, neuropeptides, and other therapeutic substances through the endothelial capillaries (BBB) for CNS therapeutics. In addition, the use of ultrasound in delivery of therapeutic agents/biomolecules such as proline rich peptides, prodrugs, radiopharmaceuticals, proteins, immunoglobulins, and chimeric peptides to the target sites in deep tissue locations inside tumor sites of brain has been explained. In addition, therapeutic applications of various types of nanoparticles such as chitosan based nanomers, dendrimers, carbon nanotubes, niosomes, beta cyclodextrin carriers, cholesterol mediated cationic solid lipid nanoparticles, colloidal drug carriers, liposomes, and micelles have been discussed with their recent advancements. Emphasis has been given on the need of physiological and therapeutic optimization of existing drug delivery methods and their carriers to deliver therapeutic amount of drug into the brain for treatment of various neurological diseases and disorders. Further, strong recommendations are being made to develop nanosized drug carriers/vehicles and noninvasive therapeutic alternatives of conventional methods for better therapeutics of CNS related diseases. Hence, there is an urgent need to design nontoxic biocompatible drugs and develop noninvasive delivery methods to check posttreatment clinical fatalities in neuropatients which occur due to existing highly toxic invasive drugs and treatment methods.

Стилі APA, Harvard, Vancouver, ISO та ін.

36

La Manna, Sara, Concetta Di Natale, Valentina Onesto, and Daniela Marasco. "Self-Assembling Peptides: From Design to Biomedical Applications." International Journal of Molecular Sciences 22, no. 23 (November 23, 2021): 12662. http://dx.doi.org/10.3390/ijms222312662.

Повний текст джерела

Анотація:

Self-assembling peptides could be considered a novel class of agents able to harvest an array of micro/nanostructures that are highly attractive in the biomedical field. By modifying their amino acid composition, it is possible to mime several biological functions; when assembled in micro/nanostructures, they can be used for a variety of purposes such as tissue regeneration and engineering or drug delivery to improve drug release and/or stability and to reduce side effects. Other significant advantages of self-assembled peptides involve their biocompatibility and their ability to efficiently target molecular recognition sites. Due to their intrinsic characteristics, self-assembled peptide micro/nanostructures are capable to load both hydrophobic and hydrophilic drugs, and they are suitable to achieve a triggered drug delivery at disease sites by inserting in their structure’s stimuli-responsive moieties. The focus of this review was to summarize the most recent and significant studies on self-assembled peptides with an emphasis on their application in the biomedical field.

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Salmaso, Stefano, Sara Bersani, Alessandra Semenzato, and Paolo Caliceti. "Nanotechnologies in Protein Delivery." Journal of Nanoscience and Nanotechnology 6, no. 9 (September 1, 2006): 2736–53. http://dx.doi.org/10.1166/jnn.2006.456.

Повний текст джерела

Анотація:

The growth rate for biotech drugs, namely proteins, peptides, and oligonucleotides, is dictated by the parallel progresses in biotechnology and nanotechnology. Actually, biotechnology techniques have expanded enormously the arsenal of therapeutically useful peptides and proteins making these products of primary interest for future pharmaceutical market. Nevertheless, the exploitation of protein and peptide drugs is strictly related to the development of innovative delivery systems which should provide for controlled, prolonged, or targeted delivery, improved stability during storage and delivery, reduced adverse effects, increased bioavailability, improved patient compliance and allow for administration through the desired route and cope with cost-containment therapeutic protocols. Colloidal formulations ideally possess the physicochemical and biopharmaceutical requisites for protein delivery. Pharmaceutical nanotechnology is a tool of techniques applied to design, develop and produce these systems. It involves the investigation of innovative materials and production procedures for preparation of a variety of nanosized dosage forms, which range from solid nanoparticles to soluble bioconjugates. The research and development of innovative tailor made protein delivery systems, which must be designed according to the drug candidate pharmacological and physicochemical properties, is one of the primary aim of modern pharmaceutical technology. Therefore, as an unmet need exists for technologies that combine innovative drug delivery solutions, a close un-prejudicial interaction between academic and industrial researchers as well as business thought leaders is required.

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Sánchez-Navarro, Macarena, and Ernest Giralt. "Peptide Shuttles for Blood–Brain Barrier Drug Delivery." Pharmaceutics 14, no. 9 (September 5, 2022): 1874. http://dx.doi.org/10.3390/pharmaceutics14091874.

Повний текст джерела

Анотація:

The blood–brain barrier (BBB) limits the delivery of therapeutics to the brain but also represents the main gate for nutrient entrance. Targeting the natural transport mechanisms of the BBB offers an attractive route for brain drug delivery. Peptide shuttles are able to use these mechanisms to increase the transport of compounds that cannot cross the BBB unaided. As peptides are a group of biomolecules with unique physicochemical and structural properties, the field of peptide shuttles has substantially evolved in the last few years. In this review, we analyze the main classifications of BBB–peptide shuttles and the leading sources used to discover them.

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Teixeira, Maria C., Claudia Carbone, Maria C. Sousa, Marta Espina, Maria L. Garcia, Elena Sanchez-Lopez, and Eliana B. Souto. "Nanomedicines for the Delivery of Antimicrobial Peptides (AMPs)." Nanomaterials 10, no. 3 (March 20, 2020): 560. http://dx.doi.org/10.3390/nano10030560.

Повний текст джерела

Анотація:

Microbial infections are still among the major public health concerns since several yeasts and fungi, and other pathogenic microorganisms, are responsible for continuous growth of infections and drug resistance against bacteria. Antimicrobial resistance rate is fostering the need to develop new strategies against drug-resistant superbugs. Antimicrobial peptides (AMPs) are small peptide-based molecules of 5–100 amino acids in length, with potent and broad-spectrum antimicrobial properties. They are part of the innate immune system, which can represent a minimal risk of resistance development. These characteristics contribute to the description of these molecules as promising new molecules in the development of new antimicrobial drugs. However, efforts in developing new medicines have not resulted in any decrease of drug resistance yet. Thus, a technological approach on improving existing drugs is gaining special interest. Nanomedicine provides easy access to innovative carriers, which ultimately enable the design and development of targeted delivery systems of the most efficient drugs with increased efficacy and reduced toxicity. Based on performance, successful experiments, and considerable market prospects, nanotechnology will undoubtedly lead a breakthrough in biomedical field also for infectious diseases, as there are several nanotechnological approaches that exhibit important roles in restoring antibiotic activity against resistant bacteria.

Стилі APA, Harvard, Vancouver, ISO та ін.

40

O'Callaghan, C. "Targeting Drug Delivery to the Lungs by Inhalation." Mediators of Inflammation 3, no. 7 (1994): S31—S33. http://dx.doi.org/10.1155/s0962935194000724.

Повний текст джерела

Анотація:

Most drugs targeted to the respiratory tract are used for their local action. For example, ephidrine for nasal decongestion, beta-2 agonists for bronchodilatation, and inhaled steroids to suppress the inflammation seen in asthmatic airways. Since the drug is delivered directly to its required site, only a small quantity is needed for an adequate therapeutic response, and consequently there is a low incidence of systemic side effects compared with oral or intravenous administration. More recently, it has become apparent that the lining of the respiratory tract, from nasal mucosa to airways and alveoli, may be used for the absorption of a drug for its systemic effect. This route of administration may be particularly attractive if it avoids the metabolic destruction encountered when some drugs are administered by alternative routes (for instance, peptides and proteins are rapidly destroyed by peptidases when Oven by the oral route). If there is a lack ofclinical response to an aerosolized drug, it is important to question whether the drug has failed or whether delivery to the site of action is inadequate. To deliver therapeutic agents by inhalation to the lower respiratory tract, inhaled drug particles must have appropriate aerodynamic characteristics. In addition, the anatomy and pathophysiology of the patient's respiratory tract, mode of inhalation through the inhaler, and the characteristics of the inhalational device itself, may significantly affect drug deposition.

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Yıldız-Peköz, Ayca, and Carsten Ehrhardt. "Advances in Pulmonary Drug Delivery." Pharmaceutics 12, no. 10 (September 23, 2020): 911. http://dx.doi.org/10.3390/pharmaceutics12100911.

Повний текст джерела

Анотація:

Pulmonary drug delivery represents an attractive, non-invasive administration option. In addition to locally acting drugs, molecules that are intended to produce systemic effects can be delivered via the pulmonary route. Several factors need to be considered in the context of delivering drugs to or via the lungs—in addition to the drug itself, its formulation into an appropriate inhalable dosage form of sufficient stability is critical. It is also essential that this formulation is paired with a suitable inhaler device, which generates an aerosol of a particle/droplet size that ensures deposition in the desired region of the respiratory tract. Lastly, the patient’s (patho-) physiology and inhalation manoeuvre are of importance. This Special Issue brings together recent advances in the areas of inhalation device testing, aerosol formulation development, use of in vitro and in silico models in pulmonary drug deposition and drug disposition studies, and pulmonary delivery of complex drugs, such as vaccines, antibiotics and peptides, to or via the lungs.

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Azama, Asad Muhammad, and Tahir Iqbal Awan. "Review Nanocarriers for the Oral Delivery of Drugs With Special Focus on Porous Silicon: A Review." Pakistan Journal of Scientific & Industrial Research Series A: Physical Sciences 64, no. 1 (March 1, 2021): 84–96. http://dx.doi.org/10.52763/pjsir.phys.sci.64.1.2021.84.96.

Повний текст джерела

Анотація:

The focus concerning controlled drug release requires the growth of appropriate drug carriers that could move adequate amount of the drug to injured area with controlled and sustained manner. A variety of nanoparticles including magnetic nanoparticles, the staes, liposomes, polymers dendrimers, solid lipid nanoparticles (SLN) and porous silicon have been investigated as drug carriers in drug delivery cases. Nanocarriers have achieved significant importance in the stabilization of proteins and peptides, anti-cancer drug camptothecin (CPT) and bone tissue engineering offering improved buccal access and protection according to the desired function. Moreover, tailored formulation along with functionalization and bio- compatibility has importance in fabrication of nanoparticles for proteins or peptides via oral delivery systems, which has advantage over parenteric delivery systems because of their comfort running and observance to treatment. The review summarizes interesting approaches on existing publications for drugs such as proteins or peptides carrier nanoparticles with special focus on porous silicon for delivery systems. Fabricatioan of nanoparticles e.g. porous silicon nanocarriers for oral delivery, advantages and disadvantages, prospective use of porous silicon in drug delivery systems will be addressed.

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Turrina, Chiara, Sonja Berensmeier, and Sebastian P. Schwaminger. "Bare Iron Oxide Nanoparticles as Drug Delivery Carrier for the Short Cationic Peptide Lasioglossin." Pharmaceuticals 14, no. 5 (April 24, 2021): 405. http://dx.doi.org/10.3390/ph14050405.

Повний текст джерела

Анотація:

New drug delivery systems are a potential solution for administering drugs to reduce common side effects of traditional methods, such as in cancer therapy. Iron oxide nanoparticles (IONs) can increase the drugs’ biological activity through high binding efficiency and magnetically targeted drug delivery. Understanding the adsorption and release process of a drug to the carrier material plays a significant role in research to generate an applicable and controlled drug delivery system. This contribution focuses on the binding patterns of the peptide lasioglossin III from bee venom on bare IONs. Lasioglossin has a high antimicrobial behavior and due to its cationic properties, it has high binding potential. Considering the influence of pH, the buffer type, the particle concentration, and time, the highest drug loading of 22.7% is achieved in phosphate-buffered saline. Analysis of the desorption conditions revealed temperature and salt concentration sensitivity. The nanoparticles and peptide-ION complexes are analyzed with dynamic light scattering, zeta potential, and infrared spectroscopy. Additionally, cytotoxicity experiments performed on Escherichia coli show higher antimicrobial activity of bound lasioglossin than of the free peptide. Therefore, bare IONs are an interesting platform material for the development of drug-delivery carriers for cationic peptides.

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Pentlavalli, Sreekanth, Sophie Coulter, and Garry Laverty. "Peptide Nanomaterials for Drug Delivery Applications." Current Protein & Peptide Science 21, no. 4 (April 29, 2020): 401–12. http://dx.doi.org/10.2174/1389203721666200101091834.

Повний текст джерела

Анотація:

Self-assembled peptides have been shown to form well-defined nanostructures which display outstanding characteristics for many biomedical applications and especially in controlled drug delivery. Such biomaterials are becoming increasingly popular due to routine, standardized methods of synthesis, high biocompatibility, biodegradability and ease of upscale. Moreover, one can modify the structure at the molecular level to form various nanostructures with a wide range of applications in the field of medicine. Through environmental modifications such as changes in pH and ionic strength and the introduction of enzymes or light, it is possible to trigger self-assembly and design a host of different self-assembled nanostructures. The resulting nanostructures include nanotubes, nanofibers, hydrogels and nanovesicles which all display a diverse range of physico-chemical and mechanical properties. Depending on their design, peptide self-assembling nanostructures can be manufactured with improved biocompatibility and in vivo stability and the ability to encapsulate drugs with the capacity for sustained drug delivery. These molecules can act as carriers for drug molecules to ferry cargo intracellularly and respond to stimuli changes for both hydrophilic and hydrophobic drugs. This review explores the types of self-assembling nanostructures, the effects of external stimuli on and the mechanisms behind the assembly process, and applications for such technology in drug delivery.

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Lu, Haijiao, Jingkang Wang, Ting Wang, Jian Zhong, Ying Bao, and Hongxun Hao. "Recent Progress on Nanostructures for Drug Delivery Applications." Journal of Nanomaterials 2016 (2016): 1–12. http://dx.doi.org/10.1155/2016/5762431.

Повний текст джерела

Анотація:

With the rapid development of nanotechnology, the convergence of nanostructures and drug delivery has become a research hotspot in recent years. Due to their unique and superior properties, various nanostructures, especially those fabricated from self-assembly, are able to significantly increase the solubility of poorly soluble drugs, reduce cytotoxicity toward normal tissues, and improve therapeutic efficacy. Nanostructures have been successfully applied in the delivery of diverse drugs, such as small molecules, peptides, proteins, and nucleic acids. In this paper, the driving forces for the self-assembly of nanostructures are introduced. The strategies of drug delivery by nanostructures are briefly discussed. Furthermore, the emphasis is put on a variety of nanostructures fabricated from various building materials, mainly liposomes, polymers, ceramics, metal, peptides, nucleic acids, and even drugs themselves.

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Bhargavi Ram, Thimmiah, Chien Chien Belinda Tang, Siaw Fui Kiew, Sie Yon Lau, Gobi Gobi, Jeevanandam Jaison, and Michael K. Danquah. "Nanoformulation of Peptides for Pharmaceutical Applications: In Vitro and In Vivo Perspectives." Applied Sciences 12, no. 24 (December 13, 2022): 12777. http://dx.doi.org/10.3390/app122412777.

Повний текст джерела

Анотація:

Peptides are short sequences of proteins consisting of two or more amino acids that are linked by peptide bonds. Peptide-based designs and drug deliveries can offer several advantages, such as antioxidant, antimicrobial, antihypertensive activities, along with immunomodulatory and antithrombotic properties, with hormone or drug-like potential. Peptide-based therapeutic formulations are used as drug candidates for the treatment of various diseases. However, there are several concerns associated with the efficacy of peptides in pharmaceutical design and delivery, including rapid degradation, limited solubility, and poor permeability. The nanoformulation of peptides has been identified as a promising approach for improving the stability of peptides and providing metabolic stability and bioavailability. This article provides an overview of the advances in the development of peptides for drug design and formulation applications. It discusses various peptide nanoformulation approaches as well as recent developments in the in vitro and in vivo analyses of nanoformulated peptides for pharmaceutical applications.

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Kong, Xu-Dong, and Christian Heinis. "Towards the Development of Orally Available Peptide Therapeutics." CHIMIA International Journal for Chemistry 75, no. 6 (June 30, 2021): 514–17. http://dx.doi.org/10.2533/chimia.2021.514.

Повний текст джерела

Анотація:

Peptides have a number of attractive properties that make them an interesting modality for drug development, including their ability to bind challenging targets, their high target specificity, and their non-toxic metabolic products. However, a major limitation of peptides as drugs is their typically poor oral availability, hindering their convenient and flexible application as pills. Of the more than 60 approved peptide drugs, the large majority is not orally applicable. The oral delivery of peptides is hampered by their metabolic instability and/or limited intestinal uptake. In this article, we review the barriers peptides need to overcome after their oral administration to reach disease targets, we highlight two recent successes of pharma companies in developing orally applicable peptide drugs, and we discuss efforts of our laboratory towards the generation of bioavailable cyclic peptides.

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Falanga, Annarita, Lucia Lombardi, Emilia Galdiero, Valentina Del Genio, and Stefania Galdiero. "The world of cell penetrating: the future of medical applications." Future Medicinal Chemistry 12, no. 15 (August 2020): 1431–46. http://dx.doi.org/10.4155/fmc-2020-0140.

Повний текст джерела

Анотація:

Cell-penetrating peptides present huge biomedical applications in a variety of pathologies, thanks to their ability to penetrate membranes and carry a variety of cargoes inside cells. Progress in peptide synthesis has produced a greater availability of virtually any synthetic peptide, increasing their attractiveness. Most molecules when associated to a cell-penetrating peptides can be delivered into a cell, however, understanding of the critical factors influencing the uptake mechanism is of paramount importance to construct nanoplatforms for effective delivery in vitro and in vivo in medical applications. Focus is now on the state-of-art of the mechanisms enabling therapeutics/diagnostics to reach the site target of their activities, and in support of scientists developing platforms for drug delivery and personalized therapies.

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Cahill, K. "Cell-penetrating peptides, electroporation and drug delivery." IET Systems Biology 4, no. 6 (November 1, 2010): 367–78. http://dx.doi.org/10.1049/iet-syb.2010.0007.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Wei, Xiaoli, Jie Gao, Changyou Zhan, Cao Xie, Man Ying, and Weiyue Lu. "Stable peptides mediated glioma targeting drug delivery." Nanomedicine: Nanotechnology, Biology and Medicine 12, no. 2 (February 2016): 557. http://dx.doi.org/10.1016/j.nano.2015.12.309.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Статті в журналах з теми "Peptides drug delivery"

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями